A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Diabetic Kidney Disease (DKD) Who Are Receiving Irbesartan
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Irbesartan/propagermanium (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ACTION
- Sponsors Dimerix Bioscience
- 26 Sep 2019 Status changed from recruiting to active, no longer recruiting, according to a Dimerix Bioscience media release.
- 17 Sep 2019 According to a Dimerix Bioscience media release, the company plans to open additional eight sites over the next two months across Melbourne, Sydney, Gold Coast and Brisbane in Australia.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.